Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Molecular Testing Panel in the Community Setting ("DINOSAur")

Glendale Adventist Medical Center d/b/a Adventist Health Glendale

Status: Enrolling

Conditions: Stage III Solid Tumors; Stage IV Solid Tumors

Treatments: Other: EORTC QLQ-30; Diagnostic Test: Comprehensive molecular panel test

Study type: Observational

Funder types: Other

Identifiers

NCT05692466

DINOSAur

Details and patient eligibility

About

To prospectively identify cancer patients whose tumors express specific molecular markers targeted by therapeutic agents from a comprehensive molecular test, for the purpose of selecting the most clinically appropriate treatment in a pragmatic two arm trial.

Enrollment: 572 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who have given informed consent in accordance with the methods and procedures of this study
• Diagnosis of cancer (stage 3 and stage 4; solid tumors only) requiring medical care
• Patients who have not received treatment related to his/her cancer
• Patients who are willing to sign a release of medical records to the research team
• Male and female patients ≥18 years of age
• Patients under oncology care of a participating site
• Sufficient clinical status for collection of biospecimen samples within usual care
• Patients who have insurance coverage for CMT

Exclusion criteria

• Patients considered minors in the jurisdiction where the protocol is conducted.
• Patients who are prisoners and pregnant women.
• Patients who cannot provide consent and did not sign a power of attorney.

Trial design

572 participants in 2 patient groups

Active

Description:

Newly diagnosed cancer patients.

Treatment:

Other: EORTC QLQ-30

Diagnostic Test: Comprehensive molecular panel test

Control

Description:

Historically diagnosed cancer patients.